\n \n \n “. concat(self. i18n. t(‘search. voice. recognition_retry’), “\n
It follows the announcement through the CDC and the World Health Organization (WHO) that the United States now meets the criteria for a country where vaccine-derived poliovirus (cVDPV) circulates.
Planned wastewater monitoring and patient diagnostic testing
New York, NY and Tel Aviv, ISRAEL, September 14, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and similar response company, announced today The CLIA/CAP qualified laboratory Provista Diagnostics has introduced a validation plan for the detection of polio through PCR. The company intends to validate several PCR tests for polio, adding tests in wastewater with ultra-high sensitivity. Low viral load diagnostic tests will be developed for early diagnosis. and will be available to multiplex with our other PCR panels.
The global bioinformatics market was priced at $13. 2 billion in 2021 according to Precedence Research and is forecast to grow at a CAGR of 16. 3% to reach $45. 6 billion through 2030. This market includes control and knowledge generation, knowledge storage, and knowledge extraction for life sciences, academia, and implemented testing. A much smaller subset of this market is wastewater-based epidemiology (WBE), which monitors giant population groups in an unobtrusive way. Routine testing can be used to collect information on unreported viral illnesses, consistent with Early Pathogen Detection in a network. 58 countries gather this knowledge to make political decisions. During COVID-19 outbreaks, sewage patterns were analyzed and have become predictive of subsequent outbreaks. The average site typically conducts weekly or twice weekly screenings and is reimbursed up to $940 consistent with the site consistent with the week based on some recent CDC awards. “Sewage tracking has become a difficult tool that must be constantly implemented on a national level now that COVID, MonkeyPox and polio are circulating in the United States,” said Gerald E. Commissiong, President and CEO. control of Todos Medical. “Surveillance testing is an essential tool for the network spread of these emerging viral pathogens. The lack of investment for large-scale testing makes sewage monitoring our first line of defense in detecting outbreaks. Given the huge price tag of wastewater research knowledge, policymakers can use it to put COVID mitigation efforts into action, so we felt it was vital for us to be able to offer this service. to our emerging visitor base for our COVID, ICU, Respiratory, GI, Wound, and STD Long PCR Panels.
About Todos Medical Ltd. Founded in Rehovot, Israel, with offices in New York, Todos Medical Ltd. (OTCQB: TOMDF) designs life-saving diagnostic responses for the early detection of various types of cancer. All of the company’s biochemical Infrared Assays (TBIA) and patented is a patented generation of cancer screening that employs peripheral blood research that examines the influence of cancer on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. The two in-house developed cancer screening tests through Todos, TMB-1 and TMB-2, have obtained the CE mark in Europe. All recently acquired the American medical diagnostics company Provista Diagnostics, Inc. to download the rights to their CLIA/CAP certified lab based in Alpharetta, Georgia, which is lately conducting COVID PCR testing, COVID and breast cancer long panel research. Pecho Videssa® at the level of exclusive advertising of blood tests provided. Provided has also launched several PCR-based tests, adding MonkeyPox, Urinary Tract Infection, Gastrointestinal (GI), Respiratory Pathogen and Wounds. Data on the Provided panels can be found in www. provistadx. com.
All are also performing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer’s disease. Lymphocyte Proliferation Control (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to be exogenous mitogens. stimulation that activates them to enter the mobile cycle. Some diseases, including Alzheimer’s disease, are thought to be the result of compromised mobile machinery leading to aberrant re-entry of the mobile cycle through neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a replacement for neuronal mobile function, suggesting a non-unusual dating between PBLs and neurons in the brain.
All formed the majority-owned joint venture based in Israel 3CL Pharma, Ltd. with NLC Pharma in March 2022 to consolidate all intellectual assets around 3CL protease-based diagnostic tests and the progression of botanical and pharmaceutical 3CL protease inhibitors that target a basic reproductive system. . 3CL Pharma, through the Brand Todos, has announced the immune supplement 3CL protease inhibitor Tollovid™ in the United States, is introducing the anti-cytokine curative drug candidate and protease inhibitor 3CL Tollvir™, while also presenting the diagnosis of 3CL protease TolloTest™.
To purchase Tollovid, visit Amazon or www. MyTollovid. com. For more information, visit https://www. todosmedical. com/.
Forward-Looking Statements Certain statements contained in this press release may possibly constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical trials and clinical progression systems. These forward-looking statements are based solely on existing control expectations and are subject to vital dangers and uncertainties that may also cause actual effects to differ materially from those described in the forward-looking statements, adding dangers and uncertainties related to the ProgressArray timing, burden and effects of clinical trials and product progression systems; difficulties or delays in discharging regulatory approval or patent coverage for candidate products; festival of other biogeneration companies; and our ability to offload the additional funding necessary to carry out our research, development and commercialization activities. In addition, the following factors, among others, may also cause actual effects to differ materially from those described in the forward-looking statements: adjustments to generation and market requirements; delays or obstacles in starting our clinical trials; adjustments in the legislation; failure to expand and introduce new technologies, products and programs in a timely manner; lack of validation of our generation as we move forward and lack of acceptance of our strategies throughout the clinical community; inability to retain or attract key workers whose wisdom is essential to the progression of our products; unforeseen clinical difficulties that could possibly expand with our process; final product load higher than expected; loss of market share percentage and pressure on charges resulting from the festival; and laboratory effects that do not translate to similar intelligent effects under actual conditions, which may also cause actual effects or functionality to differ materially from those implied by such forward-looking statements. Except as otherwise required by law, Todos Medical assumes no legal responsibility to publish revisions to such forward-looking statements to reflect events or events after the date hereof or to reflect the occurrence of unforeseen events. For a more detailed description of the dangers and uncertainties affecting Todos Medical, please refer to its reports filed periodically with the United States Securities and Exchange Commission.
All Corporate Contact 😀 Hirsch CFOTodos Medical917-983-4229 x 104Dan. h@todosmedical. com
All Press Contact:Kyle KappmeierJConnellyVice President 973-975-7827kkapmeier@jconnelly. com